Cardiol Res

Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access

Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc

Journal website https://www.cardiologyres.org

Original Article

Volume 3, Number 3, June 2012, pages 116-122

Sirolimus-Versus Zotarolimus-Eluting Stents in Acute Coronary Syndromes With C Type Left Anterior Descending Artery Lesions: A Three-Year Clinical Follow-Up

**Table 1.** Baseline Patient Clinical Characteristics
	Sirolimus-group (n = 74)	Zotarolimus-group (n = 80)	P value
*Data expressed mean ± SD, P < 0.05 accepted statistically significant. LVEF: Left ventricular ejection fraction; MI: Myocardial Infarction; PTCA: percutaneous revascularization; USAP: Unstable angina pectoris.
Age* (years)	59 ± 9.2	61 ± 10.2	0.4
Diabetes mellitus n (%)	32 (43.2%)	39 (48%)	0.3
Hypertension n (%)	43 (58%)	51 (63.7%)	0.6
History of smoking n (%)	48 (64%)	40 (50%)	0.3
Hyperlipidemia n (%)	44 (59%)	59 (73.7%)	0.3
LVEF (66.9 ± 5.5%)	67.5 ± 4.8	66.4 ± 6.2	0.4
USAP n (%)	59 (79.7%)	60 (75%)	0.4
MI n (%)	15 (20.2%)	20 (25%)	0.4
T.Cholesterol (mg/dL)*	211.6 ± 48.4	231.4 ± 54.3	0.8
LDL (mg/dL)*	148.3 ± 46.7	149.5 ± 47.7	0.5
HDL (mg/dL)*	36.3 ± 7.6	36.1 ± 7.9	0.5
TG (mg/dL)*	164 ± 101.7	164.2 ± 103.5	0.7
Glucose (mg/dL)*	144.1 ± 61.8	138.5 ± 45.6	0.2

Table 1. Baseline Patient Clinical Characteristics

Sirolimus-group (n = 74)

Zotarolimus-group (n = 80)

P value

*Data expressed mean ± SD, P < 0.05 accepted statistically significant. LVEF: Left ventricular ejection fraction; MI: Myocardial Infarction; PTCA: percutaneous revascularization; USAP: Unstable angina pectoris.

Age* (years)

59 ± 9.2

61 ± 10.2

0.4

Diabetes mellitus n (%)

32 (43.2%)

39 (48%)

0.3

Hypertension n (%)

43 (58%)

51 (63.7%)

0.6

History of smoking n (%)

48 (64%)

40 (50%)

0.3

Hyperlipidemia n (%)

44 (59%)

59 (73.7%)

0.3

LVEF (66.9 ± 5.5%)

67.5 ± 4.8

66.4 ± 6.2

0.4

USAP n (%)

59 (79.7%)

60 (75%)

0.4

MI n (%)

15 (20.2%)

20 (25%)

0.4

T.Cholesterol (mg/dL)*

211.6 ± 48.4

231.4 ± 54.3

0.8

LDL (mg/dL)*

148.3 ± 46.7

149.5 ± 47.7

0.5

HDL (mg/dL)*

36.3 ± 7.6

36.1 ± 7.9

0.5

TG (mg/dL)*

164 ± 101.7

164.2 ± 103.5

0.7

Glucose (mg/dL)*

144.1 ± 61.8

138.5 ± 45.6

0.2

**Table 2.** Angiographic Characteristics of Patiens in Two Groups
	Sirolimus-group (n = 74)	Zotarolimus-group (n = 80)	P value
Data expressed mean ± SD, P < 0.05 accepted statistically significant.
Stent (n)	84	92	0.2
Stent diameter (mm)	29 ± 5	28 ± 7	0.8
Stent length (mm)	31 ± 3	33 ± 5	0.2
Lesion length (mm)	27 ± 2	26 ± 4	0.1
Max. implantation pressure (atm)	16	18	0.2
Angiographic success n (%)	74 (100%)	80 (100%)	0.5

Table 2. Angiographic Characteristics of Patiens in Two Groups

Sirolimus-group (n = 74)

Zotarolimus-group (n = 80)

P value

Data expressed mean ± SD, P < 0.05 accepted statistically significant.

Stent (n)

0.2

Stent diameter (mm)

29 ± 5

28 ± 7

0.8

Stent length (mm)

31 ± 3

33 ± 5

0.2

Lesion length (mm)

27 ± 2

26 ± 4

0.1

Max. implantation pressure (atm)

0.2

Angiographic success n (%)

74 (100%)

80 (100%)

0.5

**Table 3.** Comparison of Acute, Subacute, Late and Very Late Stent Thrombosis in Groups
	Acute	Subacute	Late	Very late
MI: Myocardial Infarction; UAP: Unstable angina pectoris.
Patient n (%)	1 (1.25%)	2 (1.29%)	1 (1.35%)	1 (1.35%)
Age	69	68	49	68	66
M/F	F	F	F	M	F
Clinic	Acute MI	UAP	UAP	UAP	Acute MI
Smoking	-	-	+	+	+
Hypertension	+	-	+	+	+
DM	+	+	-	+	+
Stent type	Cypher	Endeavour	Cypher	Cypher	Cypher
Stent length	28 mm	38 mm	33 mm	33 mm	33 mm
Stent diameter	2.75 mm	3.5 mm	2.75 mm	3.0 mm	2.5 mm
Clopidogrel*	+	+	+	+	+
Aspirin	+	+	+	+	+
GpIIb/IIIa	-	+	-	-	-

Table 3. Comparison of Acute, Subacute, Late and Very Late Stent Thrombosis in Groups

Acute

Subacute

Late

Very late

MI: Myocardial Infarction; UAP: Unstable angina pectoris.

Patient n (%)

1 (1.25%)

2 (1.29%)

1 (1.35%)

Age

M/F

Clinic

Acute MI

UAP

Acute MI

Smoking

Hypertension

Stent type

Cypher

Endeavour

Cypher

Stent length

28 mm

38 mm

33 mm

Stent diameter

2.75 mm

3.5 mm

2.75 mm

3.0 mm

2.5 mm

Clopidogrel*

Aspirin

GpIIb/IIIa

**Table 4.** Clinical Characteristics of Follow-Up Patients at Three Years
	Sirolimus-group (n = 74)	Zotarolimus-group (n = 80)	P value
CABG: Coronary artery bypass grafting; MACE: Major adverse cardiac event; PCI: percutaneous coronary intervention.
Revascularization PCI n (%)
target vessel	3 (4%)	2 (2.5%)	0.3
non target-vessel	2 (2.7%)	2 (2.5%)	0.1
CABG n (%)	2 (2.7%)	2 (2.5%)	0.5
Myocardial infarction n(%)
Q-wave	2 (2.7%)	2 (2.5%)	0.5
non-Q-wave	3 (4%)	1 (1.25%)	0.2
Cardiac Death n (%)	2 (2.7%)	2 (2.5%)	0.5
MACE n (%)	14 (18%)	11 (13%)	0.2

Table 4. Clinical Characteristics of Follow-Up Patients at Three Years

Sirolimus-group (n = 74)

Zotarolimus-group (n = 80)

P value

CABG: Coronary artery bypass grafting; MACE: Major adverse cardiac event; PCI: percutaneous coronary intervention.

Revascularization PCI n (%)

target vessel

3 (4%)

2 (2.5%)

0.3

non target-vessel

2 (2.7%)

2 (2.5%)

0.1

CABG n (%)

2 (2.7%)

2 (2.5%)

0.5

Myocardial infarction n(%)

Q-wave

2 (2.7%)

2 (2.5%)

0.5

non-Q-wave

3 (4%)

1 (1.25%)

0.2

Cardiac Death n (%)

2 (2.7%)

2 (2.5%)

0.5

MACE n (%)

14 (18%)

11 (13%)

0.2